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Aim
To evaluate the efficacy of a 5 day short course of oral
prednisolone when added with levocetirizine for man-
agement of acute urticaria.
Materials and methods
Prospective, randomized clinical trial was carried out in
a teaching hospital.
All patients were asked to evaluate the severity of
pruritus on urticarial activity score (UAS).
Patients were then given oral prednisolone 30 mg for 5
days and tablet levocetirizine 5 mg twice daily for 6 weeks
and only levocetirizine tablet 5 mg twice daily for 6 weeks.
Patients’ conditions were reassessed clinically with UAS
calculated again 2 days later and again 5 days later.
Results
49 patients were enrolled; 24 patients received
prednisolone with Levocetirizine and 25 received only
Levocetirizine. The two groups had similar UAS at
enrollment (prednisolone, 4.6 ; levocetirizine ,4.4 ) , but
at 2- and 5- day follow-up the prednisolone group had
significantly lower UAS (1.4 and 0.2 versus 3.8 and 2.4
respectively) and greater clinical improvement in rash.
Response did not correlate with age, sex, or identifica-
tion of an allergen. No adverse effects were noted in
levocetirizine group. In Prednisolone group two patients
complained of gastritis.
Conclusion
At the end of 6 weeks, 3 patients from the steroid group
and 8 patients from the levocetirizine group continued to
get urticarial wheals. The addition of a prednisolone short
course improves the symptomatic and clinical response of
acute urticaria to antihistamines. Patients with steroids
improved more quickly and completely without major
adverse effects.
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